生物製劑或小分子標靶藥物於中重度異位性皮膚炎之治療角色

The Role of Biologic or Small Molecule Drug for Moderate to Severe Atopic Dermatitis

近10年來，異性皮膚炎的致病機轉和相關發炎激素訊息傳遞路徑已被揭開，因此，新型治療藥物相繼研發上市，隨著2017年美國FDA 核准生物製劑－－杜避炎(dupilumab)之後，異位性皮膚炎的治療也進入新的篇章，除此之外，近5年來，小分子標靶藥物也紛紛上市，為異位性皮膚炎提供理想的治療前景。然而，對於中重度異位性皮膚炎患者來說，生物製劑或小分子標靶藥物是唯一的治療選項嗎？在此，我們將會討論病患教育和治療選擇，如何有效治療異位性皮膚炎。

In recent decade, because of clearer about disease pathogenesis and cytokine signaling cascades of atopic dermatitis, more and more new targeted therapeutics are developed. In early 2017, FDA approves Dupixent (dupilumab) for moderate to severe atopic dermatitis in adults. After that, treatment for atopic dermatitis opens a new chapter. Besides, there is another new class, small molecule drugs, which has drawn our attention in recent 5 years. They bring new prospects in the optimal treatment of atopic dermatitis. However, is Biologic or small molecule drug the Treatment of Choice for moderate to severe atopic dermatitis patients? In this article, we discussed patient education, treatment option and how to optimally manage the course of disease.